摘要
Delta样分子4（DLIA）在恶性肿瘤高表达可导致血管发生，对恶性肿瘤的生长发育具有促进作用，其下调却可起到抗血管发生的作用，表现肿瘤组织中形成大量无功能的血管，阻碍肿瘤的生长，这一特点使其用于对血管内皮生长因子（VEGF）抑制剂耐受肿瘤的治疗。近来，DLIA单克隆抗体药物进入了临床研究，对耐受VEGF阻滞剂的肿瘤有较好的疗效，但也导致一些不良反应，如能有效预防DLL4的不良作用，将会对恶性肿瘤有更高的临床应用价值。
Up-regulation of DLIA contributes to the angiogenesis in malignant tumors, and thus promote tumor growth. While down-regulation of DLIA would cause antiangiogenesis and restrain tumor growth through forming a large number of no-function blood vessels. Thus it can be used in anti-VEGF tolerant tumors. Recently, DLL4 monoclonal antibody agents have entered clinic studies, and has achieved good curative effect in anti-VEGF tolerant tumors, but there are also some side effects. DLIA would bring higher clinic value for cancer therapy if the side effects can be prevented effectively.
出处
《国际肿瘤学杂志》
CAS
2011年第5期352-354,共3页
Journal of International Oncology
关键词
肿瘤
血管内皮生长因子类
治疗
Neoplasms
Vascular endothelial growth factors
Therapy
